Mirna for use in therapy
AssigneeKing's College London
InventorGraham Michael Lord
Life of this patent
Estimating the term…
Abstract
The present invention relates to a modified T regulatory cell (Treg) in which the level of microRNA miR-142-5p (CAUAAAGUAGAAAGCACUACU) or a variant thereof is increased or decreased. Therapeutic uses of said modified Tregs are also provided, in particular in the treatment of autoimmune diseases and cancer. Populations of said Tregs and methods of preparing such Tregs are also provided.
Claims30
A T regulatory cell (Treg) in which the level of microRNA miR-142-5p (CAUAAAGUAGAAAGCACUACU) or a variant thereof is increased or decreased.
A method for preparing Tregs suitable for use in the treatment of autoimmune disease, said method comprising the following steps:
- i) Isolating Tregs from a sample taken from a subject, preferably a blood sample;
- ii) Modifying the Tregs so that the level of miR-142-5p (CAUAAAGUAGAAAGCACUACU) or a variant thereof is increased;
- and optionally
- iii) in vitro expansion of the Treg cells.
A method for preparing Tregs suitable for use in the treatment of cancer, said method comprising the following steps:
- i) Isolating Tregs from a sample taken from a subject, preferably a blood sample;
- ii) Modifying the Tregs so that the level of miR-142-5p (CAUAAAGUAGAAAGCACUACU) or a variant thereof is decreased;
- and optionally
- iii) in vitro expansion of the Treg cells.
An agent which inhibits or reduces phosphodiesterase-3b (PDE3B) levels or activity, for use in the treatment of autoimmune disease.
A method of reducing PDE3B levels in a cell, wherein said method comprises the use of miR-142-5p (CAUAAAGUAGAAAGCACUACU) or a variant thereof.
A method of treating autoimmune disease in a subject, said method comprising the step of administrating an effective amount of an agent which inhibits or reduces PDE3B levels or activity, to said subject.
The use of an agent which inhibits or reduces PDE3B levels or activity, in the manufacture of a medicament, or composition, for the treatment of autoimmune disease.
Dependencies are inferred from the claim text.